Edition:
India

Adaptimmune Therapeutics PLC (ADAP.OQ)

ADAP.OQ on NASDAQ Stock Exchange Global Select Market

7.65USD
22 Feb 2018
Change (% chg)

-- (--)
Prev Close
$7.65
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
86,330
52-wk High
$9.70
52-wk Low
$3.88

Select another date:

Mon, Jan 8 2018

BRIEF-Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK

* ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING

BRIEF-Adaptimmune Announces Positive Safety Data From Pilot Studies With MAGE-A10 SPEAR T-Cells

* ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE

BRIEF-Adaptimmune Therapeutics Q3 loss per share $0.00

* Adaptimmune reports third quarter 2017 financial results and business updates

BRIEF-Matrix Capital reports 12.9 pct passive stake in Adaptimmune Therapeutics

* Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing Source text: (http://bit.ly/2wSEc1U)

GSK bets on pioneering cancer therapy with Adaptimmune deal

LONDON GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.

BRIEF-GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO

* Adaptimmune Therapeutics Plc - ‍GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO​

Select another date: